In a retrospective analysis, patients with colon cancer taking GLP-1 agonists had a 62% lower risk of 5-year mortality compared with those not taking the drugs. The mortality benefit was statistically ...

The World Health Organization on Monday recommended GLP-1 drugs as a tool to manage obesity in adults, marking a shift in the way the U.N. agency has historically framed obesity treatment. The WHO ...

Weight-loss drugs are coming for a new kind of customer. “You don’t need to be obese to start a GLP-1,” reads an ad from a telehealth startup, the words scrawled in icing on a cake. Another one ...

People who stopped taking weight-loss drugs before or during pregnancy were associated with greater gestational weight gain and had a higher risk of preterm delivery and gestational diabetes compared ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Within the next two weeks ...

You’re reading The Checkup With Dr. Wen, a newsletter on how to navigate medical and public health challenges. Click here to get the full newsletter in your inbox, including answers to reader ...

GLP-1 is the naturally produced hormone whose function is being mimicked by drugs like semaglutide and tirzepatide, the active ingredients in popular and highly effective weight-loss drugs like Wegovy ...

With new agreements from President Donald Trump promising lower prices on popular weight-loss drugs, the use of GLP-1 medications such as Ozempic and Mounjaro could soon surge even higher — a trend ...

Drugs like Ozempic, known collectively as GLP-1 receptor agonists, have become more widely used in recent years. Though they are approved for treating diabetes and aiding weight loss, some people take ...

The Trump administration announced its newest pharmaceutical agreement under its Most Favored Nation policy Thursday, striking deals with Novo Nordisk and Eli Lilly to sell their GLP-1 products at ...